edits for contributors and missing fo icons

rinpharma · Nov 19, 2023 · 72bd700 · 72bd700
1 parent b466904
commit 72bd700
Show file tree

Hide file tree

Showing 5 changed files with 26 additions and 3 deletions.
diff --git a/_publish.yml b/_publish.yml
diff --git a/contributors.qmd b/contributors.qmd
@@ -62,3 +62,22 @@ Ordered alphabetically by company;
 - James Black, R/Pharma executive; Roche
 - Harvey Lieberman, R/Pharma executive; Novartis
 
+## Advisory board
+
+- Cassie Milmont; Amgen
+- Lee Min; Amgen
+- Michael Blanks, R/Pharma executive; Beigene
+- Ning Leng, R/Pharma organizing committee; Genentech
+- Doug Kehlkoff, R Validation Hub Lead; Genentech
+- Michael Rimler; GSK
+- Andy Nicholls; GSK
+- Volha Tryputsen, R/Pharma organizing committee; J&J
+- Sumesh Kalappurakal; J&J
+- Mark Bynens; J&J
+- Harvey Lieberman, R/Pharma executive; Novartis
+- Shannon Pileggi; The Prostate Cancer Clinical Trials Consortium (PCCTC)
+- Mike Smith; Pfizer
+- Max Kuhn; Posit
+- Rich Ioannone; Posit
+- Paulo Bargo, R/Pharma executive
+- James Black, R/Pharma executive; Roche
diff --git a/index.qmd b/index.qmd
@@ -27,10 +27,14 @@ following topics:
 
 ::: {.callout-note icon=false}
 
-## {{< fa person-chalkboard >}} References
+## {{< fa graduation-cap >}} References
+
+[Promotional site for round-tables](https://rinpharma.github.io/positconf-roundtables-2023/)
 
 [R Validation Hub update](https://pharmar.github.io/events-rpharma2023/)
+
 [Doug's slides on the shared validated repo](https://pharmar.github.io/events-positconf2023/#/title-slide)
+
 [CAMIS - comparing differences based on tool used](https://psiaims.github.io/CAMIS/)
 
 :::
diff --git a/modern-sce.qmd b/modern-sce.qmd
@@ -57,7 +57,7 @@ Chairs: James Black and Satish Murphy
 
 ::: {.callout-note icon=false}
 
-# {{< fa list-check >}} 
+# {{< fa list >}} 
 
 - Can we have a learning series / discussion / panel on experience using a designing git flows
 - What are companies experiences across the diverse scopes we've placed onto SCEs - need to share more here.

diff --git a/validate-shiny.qmd b/validate-shiny.qmd
@@ -30,7 +30,7 @@ We have a path to R package validation - but what about shiny apps? In what cont
 
 ::: {.callout-note icon=false}
 
-# {{< fa list-check >}} 
+# {{< fa list >}} 
 
 - Can we share some common high level guidance on stratifying risk in shiny shared across companies? (Pfizer has written this already internally). 
 - Discuss if we should have an extension of R package whitepaper to cover shiny?